146 related articles for article (PubMed ID: 25790979)
1. PD-L1 Upregulation Drives Escape from Anti-CTLA4 and Radiation Therapy.
Cancer Discov; 2015 May; 5(5):OF13. PubMed ID: 25790979
[No Abstract] [Full Text] [Related]
2. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer.
Twyman-Saint Victor C; Rech AJ; Maity A; Rengan R; Pauken KE; Stelekati E; Benci JL; Xu B; Dada H; Odorizzi PM; Herati RS; Mansfield KD; Patsch D; Amaravadi RK; Schuchter LM; Ishwaran H; Mick R; Pryma DA; Xu X; Feldman MD; Gangadhar TC; Hahn SM; Wherry EJ; Vonderheide RH; Minn AJ
Nature; 2015 Apr; 520(7547):373-7. PubMed ID: 25754329
[TBL] [Abstract][Full Text] [Related]
3. Radiotherapy complements immune checkpoint blockade.
Ngiow SF; McArthur GA; Smyth MJ
Cancer Cell; 2015 Apr; 27(4):437-8. PubMed ID: 25873170
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy: A triple blow for cancer.
Leavy O
Nat Rev Cancer; 2015 May; 15(5):258-9. PubMed ID: 25833214
[No Abstract] [Full Text] [Related]
5. Tumour immunology: A triple blow for cancer.
Leavy O
Nat Rev Immunol; 2015 May; 15(5):265. PubMed ID: 25814401
[No Abstract] [Full Text] [Related]
6. Immunotherapy: Combined immunoradiotherapy reinvigorates antitumour immunity.
Killock D
Nat Rev Clin Oncol; 2015 Jun; 12(6):311. PubMed ID: 25801818
[No Abstract] [Full Text] [Related]
7. Radiotherapy and immune checkpoint blockade: potential interactions and future directions.
Binder DC; Fu YX; Weichselbaum RR
Trends Mol Med; 2015 Aug; 21(8):463-5. PubMed ID: 26091823
[TBL] [Abstract][Full Text] [Related]
8. The benefits of immunotherapy combinations.
Schmidt C
Nature; 2017 Dec; 552(7685):S67-S69. PubMed ID: 29293245
[No Abstract] [Full Text] [Related]
9. Immunotherapy and Checkpoint Inhibitors in Recurrent and Metastatic Head and Neck Cancer.
Hashemi-Sadraei N; Sikora AG; Brizel DM
Am Soc Clin Oncol Educ Book; 2016; 35():e277-82. PubMed ID: 27249733
[TBL] [Abstract][Full Text] [Related]
10. Combining forces: the promise and peril of synergistic immune checkpoint blockade and targeted therapy in metastatic melanoma.
Hermel DJ; Ott PA
Cancer Metastasis Rev; 2017 Mar; 36(1):43-50. PubMed ID: 28181070
[TBL] [Abstract][Full Text] [Related]
11. Inhibitors of Cytotoxic T Lymphocyte Antigen 4 and Programmed Death 1/Programmed Death 1 Ligand for Metastatic Melanoma, Dual Versus Monotherapy-Summary of Advances and Future Directions for Studying These Drugs.
Loo K; Daud AI
Cancer J; 2017; 23(1):3-9. PubMed ID: 28114249
[TBL] [Abstract][Full Text] [Related]
12. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
13. Advances in the Immunobiological Therapies for Advanced Melanoma.
Pérez Gago MC; Saavedra Santa Gadea O; de la Cruz-Merino L
Actas Dermosifiliogr; 2017 Oct; 108(8):721-728. PubMed ID: 28388991
[TBL] [Abstract][Full Text] [Related]
14. Novel Immunologic Approaches to Melanoma Treatment.
Escandell I; Martín JM; Jordá E
Actas Dermosifiliogr; 2017 Oct; 108(8):708-720. PubMed ID: 28527857
[TBL] [Abstract][Full Text] [Related]
15. Macrophage Polarization Contributes to Glioblastoma Eradication by Combination Immunovirotherapy and Immune Checkpoint Blockade.
Saha D; Martuza RL; Rabkin SD
Cancer Cell; 2017 Aug; 32(2):253-267.e5. PubMed ID: 28810147
[TBL] [Abstract][Full Text] [Related]
16. Checkpoint Immunotherapy: Picking a Winner.
Teng MW; Khanna R; Smyth MJ
Cancer Discov; 2016 Aug; 6(8):818-20. PubMed ID: 27485001
[TBL] [Abstract][Full Text] [Related]
17. [Immune-checkpoints: the new anti-cancer immunotherapies].
Ileana E; Champiat S; Soria JC
Bull Cancer; 2013 Jun; 100(6):601-10. PubMed ID: 23735730
[TBL] [Abstract][Full Text] [Related]
18. Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade.
Benci JL; Xu B; Qiu Y; Wu TJ; Dada H; Twyman-Saint Victor C; Cucolo L; Lee DSM; Pauken KE; Huang AC; Gangadhar TC; Amaravadi RK; Schuchter LM; Feldman MD; Ishwaran H; Vonderheide RH; Maity A; Wherry EJ; Minn AJ
Cell; 2016 Dec; 167(6):1540-1554.e12. PubMed ID: 27912061
[TBL] [Abstract][Full Text] [Related]
19. PD-L1 and immune escape: insights from melanoma and other lineage-unrelated malignancies.
Frydenlund N; Mahalingam M
Hum Pathol; 2017 Aug; 66():13-33. PubMed ID: 28694003
[TBL] [Abstract][Full Text] [Related]
20. [The "immune checkpoints", how does it work].
Granier C; Soumelis V; Mandavit M; Gibault L; Belazzoug R; de Guillebon E; Badoual C; Tartour E; Roussel H
Ann Pathol; 2017 Feb; 37(1):18-28. PubMed ID: 28160999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]